Nephro Care India
Listing performance
Scheduled dates
Tentative timetable — a past date is not confirmation the step completed
Issue details
- IPO date
- 28 Jun 2024 – 02 Jul 2024
- Listing date
- 05 Jul 2024
- Face value
- ₹10 per share
- Issue price
- ₹90 per share
- Lot size
- 1,600 shares
- Issue type
- Book Building issue
- Total issue size
- ₹41.26 Cr
- Market cap at offer price
- ₹148 Cr
- Promoter holding
- 85.02% → 61.39% pre-issue → post-issue
- ISIN
- INE0SUN01013
- Registrar
- Bigshare Services Pvt.Ltd.
- Lead managers
- Corporate Capitalventures Pvt.Ltd.
- Registered office
- Flat No-1JC-18, 5th Floor Sec-III, Salt lake Kolkata, Bidhan Nagar Sai Complex, North 24 Parganas, West Bengal
Reservation and application size
How the issue is split between investor categories, and what each may bid
| Investor category | Shares | % of net | % of total |
|---|---|---|---|
| Anchor investor · within QIB | 12,38,400 | — | — |
| Market maker | 2,30,400 | — | — |
Application size
Minimum 1,600 shares per lot, in multiples, at ₹90
| Application | Lots | Shares | Amount |
|---|---|---|---|
| Retail (min) | 1 | 1,600 | ₹1,44,000 |
| S-HNI (min) | 2 | 3,200 | ₹2,88,000 |
| S-HNI (max) | 6 | 9,600 | ₹8,64,000 |
| B-HNI (min) | 7 | 11,200 | ₹10,08,000 |
Category limits
| Category | Bid size | Cut-off |
|---|---|---|
| Retail (RII) | Up to ₹2 lakh | Yes |
| Small HNI (sNII) | ₹2 lakh – ₹10 lakh | No |
| Big HNI (bNII) | Above ₹10 lakh | No |
| Employee | Up to ₹5 lakh | Yes |
Bidding at cut-off means accepting the final issue price without naming one. Only retail and employee applicants may do so.
Anchor investors
Institutional allocation placed a day before the issue opens, carved out of the QIB portion and locked in after listing.
Valuation and performance
Valuation at offer price
| Metric | Pre-issue | Post-issue |
|---|---|---|
| EPS (₹) | 1.63 | 2.75 |
| P/E (×) | 55.21 | 32.73 |
| Price to book (×) | 8.04 | — |
| Market cap | — | ₹148 Cr |
Key performance indicators
- Return on net worth
- 24.42%
- ROCE
- 36.56%
- PAT margin
- 17.22%
- NAV per share
- ₹11.20
- Price to book
- 8.04
Single period as reported. Year-on-year movement is in the financials table below, where every period is published.
About Nephro Care India
Founded in 2014 in Kolkata by nephrologist Dr. Pratim Sengupta, Nephro Care India Limited (incorporated July 8, 2014 as a private limited company; converted to a public limited company with effect from March 5, 2024) began by delivering dialysis and renal OPD services through third-party hospitals (Sahid Khudiram Bose Hospital, Fleming Hospital and Dreamland Hospital) before opening its own daycare unit at Salt Lake in December 2021. It now runs a flagship Salt Lake clinic (which contributes almost 99% of revenue from operations) plus satellite clinics at HB 113, Salt Lake and Chandannagar, serving around 900 chronic kidney disease (CKD) patients per month with in-house dialysis units, outpatient services in nephrology, diabetology, cardiology, ophthalmology and neurology, NABL-accredited in-house pathology labs, an in-house pharmacy, advanced diagnostics, a renal nutrition department, home care, home dialysis and its 'Mukti' medico-yoga lifestyle programme. It makes money primarily from outpatient consultations and pharmacy sales (about 65%/35% of revenue), supplemented by dialysis, diagnostics and allied services; revenue from operations grew from ₹182.48 lakhs in FY21 to ₹342.44 lakhs in FY22, ₹1,709.27 lakhs in FY23 and ₹1,975.14 lakhs in the nine months ended December 31, 2023 (PAT ₹340.04 lakhs). The company is converting a leased 60-bed hospital at Madhyamgram, Kolkata into a proposed 100-bed multi-speciality hospital ('Vivacity Multi Specialty Hospital'), part-funded by IPO proceeds, and plans three more satellite clinics in West Bengal and Odisha.
Company Analysis
from RHPNephro Care India Limited operates kidney-care ('nephrology') clinics in Kolkata offering dialysis, outpatient consultations across multiple specialties, NABL-accredited pathology, diagnostics, an in-house pharmacy, home care/home dialysis and a lifestyle-support ('Mukti') programme for renal patients, spanning the healthcare services industry.
Founded in 2014 in Kolkata by nephrologist Dr. Pratim Sengupta, Nephro Care India Limited (incorporated July 8, 2014 as a private limited company; converted to a public limited company with effect from March 5, 2024) began by delivering dialysis and renal OPD services through third-party hospitals (Sahid Khudiram Bose Hospital, Fleming Hospital and Dreamland Hospital) before opening its own daycare unit at Salt Lake in December 2021. It now runs a flagship Salt Lake clinic (which contributes almost 99% of revenue from operations) plus satellite clinics at HB 113, Salt Lake and Chandannagar, serving around 900 chronic kidney disease (CKD) patients per month with in-house dialysis units, outpatient services in nephrology, diabetology, cardiology, ophthalmology and neurology, NABL-accredited in-house pathology labs, an in-house pharmacy, advanced diagnostics, a renal nutrition department, home care, home dialysis and its 'Mukti' medico-yoga lifestyle programme. It makes money primarily from outpatient consultations and pharmacy sales (about 65%/35% of revenue), supplemented by dialysis, diagnostics and allied services; revenue from operations grew from ₹182.48 lakhs in FY21 to ₹342.44 lakhs in FY22, ₹1,709.27 lakhs in FY23 and ₹1,975.14 lakhs in the nine months ended December 31, 2023 (PAT ₹340.04 lakhs). The company is converting a leased 60-bed hospital at Madhyamgram, Kolkata into a proposed 100-bed multi-speciality hospital ('Vivacity Multi Specialty Hospital'), part-funded by IPO proceeds, and plans three more satellite clinics in West Bengal and Odisha.
Objects of the Issue
- Setting up a Multi Speciality Hospital in the name of 'Vivacity Multi Specialty Hospital' (unit of Nephro Care) at Kolkata (Madhyamgaram), West Bengal Upto ₹2,615.34 lakhs p.76
- General Corporate Expenses/Purposes p.76
Issue Structure
- Total Issue
- 45,84,000 Equity Shares aggregating to ₹ [●] Lakhs
- Fresh Issue
- 45,84,000 Equity Shares aggregating to ₹ [●] Lakhs
- Offer for Sale
- Nil (Not applicable as the entire issue constitutes of fresh issue of equity shares)
- Price Band
- ₹ 85 to ₹ 90 per equity share of face value of ₹ 10/- each
- Lot Size
- Minimum of 1,600 Equity Shares and in multiples of 1,600 Equity Shares thereafter
- Face Value
- ₹ 10 per Equity Share
Business Model
The company earns revenue from outpatient department (OPD) consultation fees, haemodialysis sessions (in-clinic and home dialysis), NABL-accredited pathology and diagnostic tests, in-house pharmacy medicine sales, home care services and fees for its 'Mukti' lifestyle programme; for the nine months ended December 31, 2023, OPD contributed ₹1,285.45 lakhs (65.08%) and pharmacy ₹689.69 lakhs (34.92%) of revenue from operations.
Business Segments
Promoters
| Name | Role | Pre-Issue | Post-Issue |
|---|---|---|---|
| Dr. Pratim Sengupta | Promoter | 84.02% | 60.66% |
| Dr. Pritam Sengupta | Promoter | — | — |
| Dr. Sutapa Sen | Promoter | — | — |
| Mr. Pradyot Kumar Sengupta | Promoter Group | 0.40% | 0.29% |
| Mrs. Shila Sengupta | Promoter Group | 0.40% | 0.29% |
| Mr. Prasenjit Sengupta | Promoter Group | 0.20% | 0.15% |
Leadership
Auto-extracted from the company's RHP using AI, with each fact linked to its source passage (hover any row to see the quote & page). Provided for research only, not investment advice — verify against the official RHP before relying on it.